Hillhouse Capital of Beijing Co-Leads $15 Million Round for Antiva

Beijing's Hillhouse Capital and Sirona Capital of Australia have co-led a $15 million Series C-1 funding for Antiva Bioscience, a South San Francisco biopharma developing topical treatments for pre-cancerous lesions caused by HPV infection. Currently, Antiva is testing its lead compound, ABI-1958, for safety and efficacy in two Phase Ib clinical trials. Antiva said Hillhouse would be helpful in forming partnerships to develop its products in China, an area of high incidence for HPV and cervical cancer. More details....

Share this with colleagues:

Original Article: Hillhouse Capital of Beijing Co-Leads $15 Million Round for Antiva

More From BioPortfolio on "Hillhouse Capital of Beijing Co-Leads $15 Million Round for Antiva"